Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas M. Schwedhelm"'
Autor:
Matthew D. Nemesure, Thomas M. Schwedhelm, Sofia Sacerdote, A. James O’Malley, Luke R. Rozema, Erika L. Moen
Publikováno v:
Applied Network Science, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Network centrality measures assign importance to influential or key nodes in a network based on the topological structure of the underlying adjacency matrix. In this work, we define the importance of a node in a network as being dependent on
Externí odkaz:
https://doaj.org/article/b8b567a1846c4679b9a670f319ed3d90
Autor:
Thomas M. Schwedhelm, Judy R. Rees, Tracy Onega, Ronnie J. Zipkin, Andrew Schaefer, Maria O. Celaya, Erika L. Moen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact
Externí odkaz:
https://doaj.org/article/57e308d57498429bb71c7531163f50c9
Autor:
Luke R. Rozema, Erika L. Moen, Sofia Sacerdote, A. James O'Malley, Matthew D. Nemesure, Thomas M. Schwedhelm
Publikováno v:
Applied Network Science, Vol 6, Iss 1, Pp 1-14 (2021)
Appl Netw Sci
Appl Netw Sci
Network centrality measures assign importance to influential or key nodes in a network based on the topological structure of the underlying adjacency matrix. In this work, we define the importance of a node in a network as being dependent on whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79e6553790b1b0a07f05128bd7e519d4
https://pubmed.ncbi.nlm.nih.gov/34938853
https://pubmed.ncbi.nlm.nih.gov/34938853
Autor:
Judy R. Rees, Thomas M. Schwedhelm, Maria O. Celaya, Ronnie Zipkin, Andrew P Schaefer, Erika L. Moen, Tracy Onega
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Background Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6700cbd1f32784ee7397cc337add169
https://pubmed.ncbi.nlm.nih.gov/32883270
https://pubmed.ncbi.nlm.nih.gov/32883270